The Brigham and Women's Hospital, Inc.

Solutex Na, Lcc

University of Southern California

Other

Boston University

University of California

National Institutes of Health (nih)

Brigham and Women's Hopsital, Inc.

Resolvyx Pharmacuticals, Inc.

Resolvyx Pharmaceuticals, Inc.

The Brigham Women's Hospital, Inc.

Charles Nicholas Serhan

Bruce D Levy

Sean P Colgan

Fernando Moreno Egea

Rong Yang

James L Madara

Nicos A Petasis

Clary B Clish

Gerhardus Lucas Bannenberg

Thomas E Van Dyke

Joan Clària Enrich

Jesmond P Dalli

Nan Chiang

Tejal Ashwin Desai

Michael R Hanley

Daniel W Goodman

Jesmond Dalli

Iolanda M Fierro

Makoto Arita

Stuart L Bursten

Michael S Conte

Reza Dana

Bengt Ingemar Samuelsson

Mats A Hamberg

Yiping Jin

Lucy V Norling

Matthew Spite

Paul Norris

Kamal Badr

Louis Simchowitz

The present invention encompasses oils that have anti-inflammatory or resolution-stimulating activity that contain or are enriched with Specialized Proresolving Mediators (SPM) or SPM precursors, which originate from an oil obtained from organisms containing long chain omega-3 polyunsaturated fatty acids, such as fish, crustaceae, algae, and mollusks. The invention also encompasses a method for the production of these oils, and the utilization of the oils for nutritional supplements, pharmaceutical formulations, and cosmetic formulations, which can be employed for treating an inflammatory condition.

Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors

The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.

Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same

The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof.

N-3 immunoresolvents: structures and actions

Disclosed herein is a method of providing a metabololipidomic profile and SPM signature on the progress of the innate host defense response following blood clotting. The method can include the step of taking one or more measurements in a patient's blood sample, wherein the sample is obtained during the time-course of clotting or coagulation or following clotting or coagulation, of pro-thrombotic and pro-inflammatory mediators (eicosanoids) and specialized pro-resolving mediators SPMs. From these measurements, a personalized metabololipidomic profile can be obtained. By comparing the measurement to that taken from normal or reference blood, a comparison profile can be developed. The profile comparison profile can then be used to make a medical or therapeutic decision.

Personalized metabolomic profiling of specialized pro-resolving mediators

Compositions comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same

New host-protective molecules containing conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and were derived from n-3 docosapentaenoic acid (DPA, C22:5) were produced in neutrophil-endothelial co-cultures, and they are present in human and mouse tissues after sterile inflammation or infection. These compounds, termed 13-series resolvins (RvT), demonstrated potent protective actions increasing mice survival duringinfections. Their biosynthesis during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 (COX-2) and increased by atorvastatin via S-nitrosylation of COX-2. Atorvastatin and RvT were additive ininfections in mice where they accelerated resolution of inflammation and increased survival &#x3e;60%. Results documented novel host protective molecules in bacterial infections, namely RvT, derived from n-3 DPA via transcellular biosynthesis and increased by atorvastatin. RvT also regulated human and mouse phagocyte responses stimulating bacterial phagocytosis and regulating inflammasome components to regulate key innate protective responses in the resolution of infectious-inflammation.

Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections

A method to determine the severity of a disease of chronic inflammation in a patient, comprising the steps of (1) collection or preparation of a bodily fluid, tissue or lavage and (2) measurement of ALX receptor ligands or ALX receptor expression in the fluid, tissue, or lavage, wherein the level of ALX receptor ligands predicts a clinical outcome or choice of treatment modality, is disclosed.

ALX receptor ligands define a biochemical endotype for inflammation-based diseases

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristics of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have an oxylipin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow/reperfusion damage.

Cysteinyl-proresolving mediators that promote resolution of infection and organ protection

Oils with anti-inflammatory activity containing natural Specialized Proresolving Mediators and their precursors

The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.

14-hydroxy-docosahexaenoic acid compounds

Growing community of inventors

Needham, MA, United States of America

Charles Nicholas Serhan